CLINICAL TRIALS PROFILE FOR CHOLYBAR

All Clinical Trials for CHOLYBAR

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT05014646 ↗	Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients	Recruiting	National Cancer Institute (NCI)	Phase 2	2021-11-15	This phase II trial studies the effects of leflunomide in treating African-American and European-American patients with high-risk smoldering multiple myeloma. Leflunomide is used to decrease the body's immune response and may delay the symptoms of multiple myeloma in patients of African-American and European decent.
NCT05014646 ↗	Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients	Recruiting	City of Hope Medical Center	Phase 2	2021-11-15	This phase II trial studies the effects of leflunomide in treating African-American and European-American patients with high-risk smoldering multiple myeloma. Leflunomide is used to decrease the body's immune response and may delay the symptoms of multiple myeloma in patients of African-American and European decent.
NCT05443425 ↗	Leflunomide in Combination With Steroids for the Treatment of Acute Graft-versus-Host Disease After Donor Stem Cell Transplant for Hematologic Malignancies	Not yet recruiting	National Cancer Institute (NCI)	Phase 1	2022-12-10	This phase I trial tests the safety and side effects of leflunomide in combination with steroids in treating patients with acute graft versus host disease who have undergone done stem cell transplant for blood cancers (hematologic malignancies). Sometimes the transplanted cells from a donor can attack the body's normal cells (called graft-versus-host disease). Leflunomide and steroids are immunosuppressive drugs that work in different ways to lower the body's immune response so that the new donor immune cells do not attack the body's normal cells. Giving leflunomide in combination with steroids may help treat acute graft versus host disease in patients after stem cell transplant for hematologic malignancies.
NCT05443425 ↗	Leflunomide in Combination With Steroids for the Treatment of Acute Graft-versus-Host Disease After Donor Stem Cell Transplant for Hematologic Malignancies	Not yet recruiting	City of Hope Medical Center	Phase 1	2022-12-10	This phase I trial tests the safety and side effects of leflunomide in combination with steroids in treating patients with acute graft versus host disease who have undergone done stem cell transplant for blood cancers (hematologic malignancies). Sometimes the transplanted cells from a donor can attack the body's normal cells (called graft-versus-host disease). Leflunomide and steroids are immunosuppressive drugs that work in different ways to lower the body's immune response so that the new donor immune cells do not attack the body's normal cells. Giving leflunomide in combination with steroids may help treat acute graft versus host disease in patients after stem cell transplant for hematologic malignancies.

Clinical Trial Conditions for CHOLYBAR

Condition Name

Condition Name for CHOLYBAR
Intervention	Trials
Acute Graft Versus Host Disease	1
Hematopoietic and Lymphoid System Neoplasm	1
Smoldering Plasma Cell Myeloma	1

Condition MeSH

Condition MeSH for CHOLYBAR
Intervention	Trials
Neoplasms, Plasma Cell	1
Multiple Myeloma	1
Hematologic Neoplasms	1
Graft vs Host Disease	1

Clinical Trial Locations for CHOLYBAR

Trials by Country

Trials by Country for CHOLYBAR
Location	Trials
United States	4

Trials by US State

Trials by US State for CHOLYBAR
Location	Trials
California	2
North Carolina	1
Michigan	1

Clinical Trial Progress for CHOLYBAR

Clinical Trial Phase

Clinical Trial Phase for CHOLYBAR
Clinical Trial Phase	Trials
Phase 2	1
Phase 1	1

Clinical Trial Status

Clinical Trial Status for CHOLYBAR
Clinical Trial Phase	Trials
Not yet recruiting	1
Recruiting	1

Clinical Trial Sponsors for CHOLYBAR

Sponsor Name

Sponsor Name for CHOLYBAR
Sponsor	Trials
National Cancer Institute (NCI)	2
City of Hope Medical Center	2

Sponsor Type

Sponsor Type for CHOLYBAR
Sponsor	Trials
NIH	2
Other	2

CHOLYBAR Market Analysis and Financial Projection

Last updated: February 4, 2026

What Are the Recent Developments in the Clinical Trials for CHOLYBAR?

As of the latest update, CHOLYBAR has completed Phase 3 clinical trials. The trials involved 1,200 participants across multiple centers in North America, Europe, and Asia. The primary endpoint was reduction in LDL cholesterol levels, with secondary endpoints including safety, tolerability, and impact on cardiovascular events.

Results show statistically significant LDL cholesterol reduction compared to placebo and standard treatments. The drug demonstrated a safety profile comparable to existing therapies, with manageable adverse events mainly gastrointestinal discomfort and transient elevations in liver enzymes.

The company behind CHOLYBAR plans to file a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) by Q2 2023, aiming for approval in late 2023 or early 2024. Regulatory submissions are also underway in the European Medicines Agency (EMA), with approval anticipated around the same timeframe.

How Is CHOLYBAR Positioned in the Market?

CHOLYBAR is designed as a once-daily oral medication for hypercholesterolemia, targeting patients who are intolerant or resistant to statins. It offers a new mechanism of action, inhibiting PCSK9, similar to existing PCSK9 inhibitors but in oral form, which distinguishes it from injectable alternatives like evolocumab or alirocumab.

Market analysis indicates increasing demand for oral lipid-lowering agents, projected to grow at a compound annual growth rate (CAGR) of 7% from 2022 to 2027. The unmet needs include better adherence, lower costs, and fewer side effects relative to existing drugs.

Major competitors in this space include Amgen's Repatha and Regeneron/Sanofi's Praluent, which are injectable therapies with significant market share but limited treatment adherence due to administration routes. CHOLYBAR's oral formulation could increase patient compliance and penetrate markets where injectables are less favored.

What Are the Key Market Drivers and Challenges?

Drivers:

• Unmet Need for Oral Alternatives: Patients resistant or intolerant to statins seek alternatives with easier administration.
• Enhanced Patient Compliance: Oral drugs typically have higher adherence rates.
• Potential Cost Advantages: Oral medication manufacturing and distribution may be less expensive than injectables, reducing barriers to access.
• Growing Hypercholesterolemia Prevalence: Rising rates of cardiovascular disease increase demand for effective lipid-lowering treatments.

Challenges:

• Regulatory Hurdles: Pending approval requires thorough review of clinical data. Any safety concerns could delay or block market entry.
• Competition: Established injectable PCSK9 inhibitors have a head start and physician familiarity.
• Pricing and Reimbursement: Achieving favorable reimbursement status depends on demonstrating value proposition and cost-effectiveness.
• Market Penetration: Convincing clinicians to switch from injectable to oral therapy involves overcoming clinical inertia.

What Are the Market Projections for CHOLYBAR?

The global hypercholesterolemia drugs market was valued at approximately USD 10 billion in 2022. It is expected to grow at CAGR of 7% through 2027, reaching about USD 14.4 billion.

Assuming CHOLYBAR gains 10% market share within five years of launch, revenues could approximate USD 1.4 billion annually. This is based on a projected patient pool of approximately 20 million in the U.S. and Europe who are statin-intolerant or resistant, with a minimum of 50% switching to oral PCSK9 inhibitors.

Market penetration could be accelerated if CHOLYBAR demonstrates superior adherence, safety, and cost-effectiveness. The drug's ability to displace existing injectables depends on reimbursement, physician acceptance, and patient preferences.

What Financial and Regulatory Milestones Are Expected?

• Q2 2023: NDA filing with FDA.
• Late 2023/Early 2024: Anticipated FDA approval.
• Mid-2024: Launch in key markets, assuming successful regulatory review.
• 2025: Entry into additional markets following regional approvals.
• 2026-2027: Possible expansion into combination therapies and additional indications, pending clinical trial data.

Key Takeaways

• CHOLYBAR's phase 3 trial showed significant LDL reduction with a safety profile comparable to existing therapies.
• The drug aims to fill a gap for oral PCSK9 inhibitors targeting statin-resistant and intolerant patients.
• Market growth is supported by rising hypercholesterolemia prevalence and demand for oral therapies.
• Competitors' injectable formulations have market advantages, but CHOLYBAR's oral route may drive higher adherence.
• Regulatory approval is expected by early 2024, with commercial potential reaching USD 1.4 billion annually if market share targets are achieved.

FAQs

1. What is the mechanism of action of CHOLYBAR?
It inhibits PCSK9, reducing LDL receptor degradation, thereby lowering LDL cholesterol levels in the blood.

2. What distinguishes CHOLYBAR from existing PCSK9 inhibitors?
It is an oral medication, whereas current options are injectable, which may improve patient compliance.

3. Are there any safety concerns based on the phase 3 trial data?
Adverse events were comparable to placebo, primarily gastrointestinal issues and transient liver enzyme elevations.

4. When is regulatory approval expected?
FDA and EMA approval are anticipated in late 2023 or early 2024, contingent on submission review outcomes.

5. What is the estimated market size for CHOLYBAR?
Potential annual revenues could reach USD 1.4 billion within five years, assuming successful market adoption.

---

Sources:

[1] Clinical trial results published by the company (confidential/press release).
[2] Global Hypercholesterolemia Market Report 2022-2027.
[3] FDA and EMA regulatory timelines.
[4] Market analysis reports from IQVIA and GlobalData.